What question did this study set out to answer?

This study aims to provide real-world data on the effectiveness and safety of chemotherapy combined with durvalumab in treating endometrial cancer.

July 4, 2026Open Access

94TiP DUOLife: Prospective non-interventional study to generate real-world-data on effectiveness and safety of first-line chemotherapy plus durvalumab followed by maintenance durvalumab or durvalumab + olaparib in endometrial cancer – Study design

Key Points

This study aims to provide real-world data on the effectiveness and safety of chemotherapy combined with durvalumab in treating endometrial cancer.
Prospective non-interventional study design
Focus on first-line treatments for endometrial cancer
Comparison of CP+D and CP+D+O regimens
1L CP plus durvalumab demonstrated effectiveness for dMMR tumours.
Durvalumab plus olaparib maintenance showed promising outcomes for pMMR tumours.

Abstract

Endometrial cancer (EC) is the most common gynaecological malignancy in Germany, accounting for about 4.6% of all cancers in women. For many years, the established first-line (1L) treatment for advanced disease was carboplatin plus paclitaxel (CP). This has changed with recent studies: adding immunotherapy to chemotherapy is now the standard of care for mismatch repair-deficient (dMMR) tumours and offers a new option for mismatch repair-proficient (pMMR) disease. DUO-E study showed benefit with 1L CP plus durvalumab, followed by durvalumab (CP+D) for dMMR tumours and durvalumab plus olaparib maintenance (CP+D+O) for pMMR tumours.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper